Zacks Investment Research News Agency
Yesterday•Zacks Investment Research
Stocks Medium Importance Neutral
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates

Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.46 per share a year ago.

Related Symbols 1
VNDA VNDA
Source: Zacks Investment Research
Visit Source
0 0 0
Comment

Comments

0
No comments yet
Be the first person to comment on this news item.